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Summary: Epithelial ovarian cancer (EOC) is a heterogeneous disease with a major heritable 25 
component. The different histotypes of invasive disease – high grade serous, clear cell, endometrioid 26 
and mucinous – are associated with different underlying genetic susceptibility and epidemiological and 27 
lifestyle risk factors, all of which contribute to the different biology and clinical characteristics of each 28 
histotype. A combination of familial and population based sequencing studies, and genome wide 29 
association studies (GWAS) have identified a range of genetic susceptibility alleles for EOC 30 
comprising rare but highly pentrant genes (e.g. BRCA1, BRCA2) that  are responsible familial 31 
clustering of ovarian cancer cases; more moderate penetrance susceptibility genes (e.g. BRIP1, 32 
RAD51C/D, MSH6); and multiple common but low pentrance susceptibility alleles identified by GWAS. 33 
Identifying genetic risk alleles for ovarian cancer has had a significant impact on disease prevention 34 
strategies; for example it is now routine clinical practice for individuals with germline BRCA1 and 35 
BRCA2 mutations to undergo risk reducing salpingo-oophorectomy. Because ovarian cancers are 36 
commonly diagnosed at a late clinical stage when the prognosis is poor, the continued development of 37 
genetic risk prediction and prevention strategies will represent an important approach to reduce 38 
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mortality due to ovarian cancer. Advances in genomics technologies that enable more high-throughout 39 
genetic testing, combined with research studies that identify additional EOC risk alleles will likely 40 
provide further opportunities to establish polygenic risk prediction approaches, based on combinations 41 
of rare high/moderate penetrance susceptibility genes and common, low penetrance susceptibility 42 
alleles. This article reviews the current literature describing the genetic and epidemiological 43 
components of ovarian cancer risk, and discusses both the opportunities and challenges in using this 44 
information for clinical risk prediction and prevention. 45 
  46 
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Epithelial Ovarian Cancer: The Clinical and Public Health Challenge:  47 
Epithelial ovarian cancer (EOC) causes around 125,000 deaths globally per year. Over the last 40 48 
years, long term survival rates have changed very little. About 70% of women with ovarian cancer are 49 
diagnosed with advanced stage disease (stages III/IV), of whom only ~30% will survive more than 5 50 
years. By contrast, women diagnosed with earlier stage (stage 1) disease have a 5-year survival rate 51 
>90%. Our understanding of the biology if EOC is limited, and complicated by disease heterogeneity. 52 
Invasive EOC represents 90% of all malignant ovarian tumors and comprises four major histological 53 
subtypes; high-grade serous, endometrioid, clear cell and mucinous which have different clinical 54 
courses and survival rates. The most common histotype is high-grade serous ovarian cancer 55 
(HGSOC) and these cases represent the major clinical problem.  The different histotypes probably 56 
have distinct cells of origin and can be characterized by different germline and somatic genetic 57 
changes that result in the perturbation of different molecular pathways.  Even within the different 58 
histotypes there is likely to be substantial clinical and molecular heterogeneity [1, 2]. The standard 59 
treatment for EOC consists of maximal cytoreductive surgery followed by administration of platinum 60 
and taxane-based chemotherapy. Most patients with advanced stage (III/IV) HGSOC initially respond 61 
well to primary treatment with surgery and chemotherapy; but cancer usually recurs with a drug-62 
resistant phenotype.  63 
Given the greatly improved survival rates associated with early stage ovarian cancer, clinical 64 
intervention strategies that either detect EOC at the earliest most treatable stages, or prevention 65 
strategies for women at greatest risk may be effective approaches to reduce the burden of EOC. 66 
Unfortunately, signs and symptoms of ovarian cancer are usually absent in early stage disease. Even when 67 
they are present, symptoms are often subtle and may vary by EOC histotype [3]. There are currently no 68 
effective screening approaches for detecting early stage EOC. Serum CA-125 testing is useful for 69 
differential disease diagnosis, but has not been shown to be an effective early-stage screening approach 70 
due to its low sensitivity and specificity [4, 5]. HE4 is another candidate ovarian cancer screening marker, 71 
although it has not been extensively tested in clinical trials [6]. Vaginal ultrasonography can also be used to 72 
detect adnexal masses consistent with ovarian cancer, but once again this does not ppear to be effective 73 
for detecting early stage EOC [7]. Using a combinations of genetic, epidemiology and lifestyle risk 74 
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factors to identify women at greatest risk of EOC in the population, followed by effective clinical 75 
intervention strategies could represent a powerful population based strategy to reduce mortality 76 
associated with the disease  77 
Genetic Epidemiology of Epithelial Ovarian Cancer  78 
Epidemiological and lifestyle risk factors: Several epidemiologic studies have suggested that 79 
exposure to endogenous and exogenous hormones play an important role in ovarian cancer etiology 80 
[8]. Oral contraceptive (OC) use [9] and parity [10] are both protective, with decreasing risks 81 
associated with increasing duration of OC use and increasing parity. Younger age at menarche, 82 
breastfeeding and hysterectomy are associated with a reduction in EOC risk, while the use of 83 
menopausal hormone therapy (MHT) (particularly estrogen only therapy), is associated with an 84 
increase in EOC risk [9, 11-16]. In a large trial, long-term post-menopausal hormone use was 85 
associated with increased EOC risk [17], which is consistent with several cohort studies [18-21]. A 86 
meta-analysis indicated a 20% increase in ovarian cancer risk per 5 years of postmenopausal 87 
estrogen use [12]. Tubal ligation is another well-established EOC risk factor [22] which is inversely 88 
associated with EOC risk. 89 
Some risk factors have been reported to be asociated with specific histotypes of ovairan 90 
cancer. Olsen et al. (2013) found obesity to be weakly associated with an increased risk of 91 
low-grade serous invasive tumors but there was no association with invasive high-grade 92 
serous ovarian cancer [23].  In the same study, high body mass index (BMI) was associated 93 
with increased risk of borderline serous, invasive endometrioid, and invasive mucinous 94 
ovarian cancer histotypes.  It is also well established that endometriosis is risk factor for clear 95 
cell and endometrioid ovarian cancer, but not for high-grade serous or mucinous histotypes 96 
[24].  A meta-analysis has found an association between smoking and mucinous EOCs, an 97 
inverse association for risks of endometrioid and clear cell EOCs, and no association with 98 
high-grade and borderline serous histotypes [25]. Menopausal hormone therapy appears to 99 
be more associated with an increased risk of serous and possibly endometrioid histotypes 100 
compared to other subtypes [15, 18]. Finally, oral contraceptive use (ever/never) is associated 101 
 5 
with reduced risk for the serous and endometrioid subtypes, with a suggestive, but not 102 
significant, increase in risk in mucinous and clear cell EOC [15]. Recent larger studies have 103 
reported reduced risk in all subtypes other than mucinous with oral contraceptive use, and an 104 
increase in risk of mucinous as duration of oral contraceptive use increases [26, 27]. 105 
Germline genetic risk factors: Family history remains one of the strongest EOC risk factors. A 106 
woman with a first-degree relative with ovarian cancer has a three-fold increased risk of developing the 107 
disease compared to women with no family history. Studies of twins show that the majority of this 108 
familial ovarian cancer risk is due to inherited genetic factors, rather than environmental and lifestyle 109 
factors shared within families [28]. Inheriting damaging mutations high risk ovarian cancer 110 
susceptibility genes is the strongest predictor of inherited risk for ovarian cancer. Mutations in two 111 
genes, BRCA1 [29] and BRCA2 [30], confer high-penetrance susceptibility to both ovarian and breast 112 
cancer [30, 31]. The risks of ovarian cancer conferred by BRCA1 and BRCA2 mutations have been 113 
estimated from both family and population based studies. In family studies, the cumulative risk of 114 
ovarian cancer by age 80 years are estimated to be 44% in BRCA1 mutation carriers and 17% in 115 
BRCA2 mutation carriers [32]. Risk estimates are generally lower in population based studies; in a 116 
combined analysis of 22 different studies average ovarian cancer risks were 39% (95% confidence 117 
interval (CI) 18%–54%) in BRCA1-mutation carriers and 11% (2.4%–19%) in BRCA2-mutation carriers 118 
[33]. The prevalence of mutations in these genes also contributes to the different risk of EOC observed 119 
in different populations. For example, BRCA1 and BRCA2 mutations are more prevalent in Ashkenzi 120 
Jewish populations  and so average lifetime risks are high in this population (54% for BRCA1 and 23% 121 
for BRCA2) [34]. These genes are responsible for most families containing multiple cases of breast 122 
and ovarian cancer [35, 36] and combined they account for approximately a third of the heritable risk 123 
of ovarian cancer [37].  However, in a study of 283 ovarian cancer families, only 27 percent of families 124 
containing just two first degree relatives with EOC were due to BRCA1 or BRCA2 mutations, which 125 
demonstrated that other ovarian cancer susceptibility alleles were likely to exist [36]. 126 
Several studies have reported that risks of ovarian and breast cancer vary depending on the location 127 
of the predicted pathogenic mutation in both BRCA1 and BRCA2 [38-42]. A recent study of ~12,000 128 
BRCA1 carriers and 7,000 BRCA2 carriers with breast and/or ovarian cancer indicated there are 129 
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increases in ovarian cancer risks with a concomitant decrease in breast cancer risk for mutations in 130 
the central portion both BRCA1 and BRCA2 [32, 38-42]. Consistent with these findings, germline 131 
BRCA murine models have shown different phenotypes for different BRCA mutations [43, 44]. Other 132 
studies have shown that common low penetrant susceptibility alleles in other genes can modify the 133 
risks of ovarian and breast cancer in BRCA1 and BRCA2 mutation carriers [45, 46].  134 
Germline BRCA1/BRCA2 mutations are observed in all non-mucinous histologic subtypes of ovarian 135 
cancer [37], but are most commonly associated with the development of the HGSOC histotype [36, 38, 136 
47-49], with around 15% HGSOC patients carrying mutations in these genes. Typically, HGSOCs are 137 
highly genomically unstable and inevitably acquire somatic TP53 mutations during the early stages of 138 
tumor development. The BRCA1 and BRCA2 proteins are involved in the maintenance of genome 139 
stability by regulating the expression of genes critical for the repair of DNA double-strand breaks 140 
(DNA-DSB) via homologous recombination and regulation of cell growth and division [50]. Double 141 
strand DNA breaks are usually introduced by DNA damaging agents such as free radicals or ionizing 142 
radiation and the conversion of single strand breaks into double strand breaks by the collapse of the 143 
replication fork during DNA replication leading to global genomic instability [51]. Next generation 144 
sequencing (NGS) approaches, including whole genome and exome sequencing and targeted gene 145 
sequencing in large epidemiological case-control series have recently identifed additional ovarian 146 
cancer susceptibility genes. Focusing particularly on DNA-DSB repair genes that complex with BRCA1 147 
and/or BRCA2, these studies have identified RAD51C, RAD51D, BRIP1 and FANCM as likely 148 
susceptibility genes particularly for the HGSOC histotype (Figure 1) [51-59]. Relative risk estimates for 149 
pathogenic mutations in these genes are more modest than BRCA1/BRCA2 ranging from ~2 for 150 
FANCM, ~4 for RAD51C, ~7 for RAD51D and ~11 for BRIP1 [51-59]. 151 
Another class of genes associated with susceptibility to ovarian cancer are the DNA mismatch repair 152 
genes (MMR). Mutations in these genes are more commonly associated with Lynch Syndrome, or 153 
hereditary non-polyposis colorectal cancer (HNPCC). This autosomal dominant syndrome is 154 
associated with increased risks of gynecological cancers, in particular endometrial cancer and the 155 
endometrioid and clear cell subtypes of ovarian cancer [60]. In the largest population-based study to 156 
estimate the prevalence of mutations in MMR genes in ovarian cancer cases, MSH2 and MSH6 in 157 
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particular showed increased prevalence of germline mutations, largely in non-serous ovarian cancer 158 
cases [61, 62], and more recently a small number of cases with mutations in PMS2 [47] and MLH1 [63] 159 
have been identified. Lifetime risk for ovarian cancer in Lynch Syndrome patients varies depending on 160 
the mutation. By age 70 risk in MLH1 is 4-20%, MSH2 (7.5-20% and MSH6 (0-13.5%) [64, 65]. 161 
Common low penetrance susceptibility alleles: There has been substantial progress in identifying 162 
common risk variants for ovarian cancer using genome wide association studies (GWAS). These 163 
studies have so far identified thirty-nine independant EOC risk regions (Table 1) [45, 46, 66-76], with 164 
each risk region associated with only modest increases in risk (relative risk less than 1.3 per risk allele 165 
carried). The majority of common variant risk alleles so far identified are associated with the HGSOC 166 
subtype, probably because this is most common subtype; but some loci identified confer risk to other 167 
subtypes including mucinous [74, 76], clear cell [69, 71, 76], endometrioid [76] and low-grade serous 168 
histotypes [70, 76] (Figure 2). There is also evidence of pleiotropy, in which the same genetic variants 169 
or different variants in the same genomic region confer risk to two or more ovarian cancer subtypes 170 
and even other cancers, particularly breast and prostate cancers [77-79]. These data suggest there 171 
may be common functional mechanisms underlying the development multiple phenotypes associated 172 
with some common variant susceptibility loci.  173 
The vast majority of confirmed common variant risk alleles are located in the non-protein-coding 174 
genome and the likely functional mechanisms are through epigenomic regulation of one or more target 175 
susceptibility genes. Where functional evidence for a target susceptibility gene at a risk locus has 176 
emerged, the data suggests that the biology of ovarian cancer development at common variant risk 177 
loci differs from that of the high and moderate pentrance genes, in that the genes are not directly 178 
involved in DNA repair. For example, functional studies have identified: HNF1B (hepatocyte nuclear 179 
factor 1 homeobox B) at the 17q12 locus as a target gene for serous and clear cell EOC subtypes, and 180 
for prostate cancer [71, 79]; the Homeobox gene HOXD9 at 2q31 as a target in high-grade serous and 181 
mucinous ovarian cancer [74, 80]; PAX8 (Paired box gene 8) on chromosome 2p13 associated with 182 
mucinous ovarian cancer [74]; ABHD8 (abhydrolase domain containing 8 gene) on chromosome 183 
19p13 associated with both ovarian and breast cancer development [81]; and OBFC1 (oligonucleotide/ 184 
oligosaccharide-binding fold containing 1) at chromosome 10q24 associated with low-grade serous 185 
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ovarian cancer [76]. Of the thirty nine risk loci identified by GWAS evidence implicating a functional 186 
gene has been reported at eight loci (Table 1), demonstrating the significant amount of biology yet to 187 
be identified.  188 
Missing Heritability: The studies summarized above report on a range of susceptibility genes and risk 189 
alleles for ovarian cancer of both varying allele frequency and risks in the population (Figure 3).  190 
However, the known susceptibility genes for ovarian cancer account for ~40% of the excess familial 191 
risks (narrow sense heritability), with common low risk variants found by GWAS contributing less than 192 
5% [82] (Figure 4). Thus, less than half the heritable component of EOC has been characterized. The 193 
remaining risk is probably due to multiple alleles including common genetic variants (>5% in the 194 
population) conferring weak effects (relative risks <1.2), and uncommon (1-5%) and rare variants 195 
(<1%) conferring weak to moderate effects with relative risks less than ten  196 
Germline genetic variation and clinical outcome in EOC patients: There is now substantial 197 
evidence that germline genetic alleles of BRCA1 and BRCA2 influence overall survival in EOC cancer 198 
cases, likely due to enhanced platinum sensitivity conferred through a breakdown in DNA repair 199 
mechanisms [37, 83, 84]. The most comprehensive of these studies showed that 200 
BRCA1 and BRCA2 mutation carriers have a more favorable short survival than non-carriers after 201 
adjusting for stage, grade, histology and age at diagnosis (BRCA1, HR=0.73, P=2×10−5; BRCA2, HR = 202 
0.49, P=3×10−10) [84]. However, more recent studies have suggested that these survival advantages 203 
to not persist, particularly in BRCA1 carriers [85-87]. To date, there is only weak evidence that that 204 
common, low penetrance susceptibility variants may also influence overall survival in ovarian cancer 205 
patients [88-92].  206 
Finding EOC susceptibility alleles associated with disease risk and outcome could have significant 207 
impacts in the clinical management of ovarian cancer cases. For example, such findings could lead to 208 
the development of novel therapies for EOC and/or may influence their disease management after 209 
stratifying patients by their germline genotypes. Indeed, the functional characterization of BRCA1/2, 210 
has already led to the development of a novel therapy for BRCA1/BRCA2 carriers based on synthetic 211 
lethality and inhibition of the poly (ADP-ribose) polymerase (PARP) DNA repair pathway. Phase I and 212 
II trials for PARP inhibitors (commonly known as olaparib) show that PARP inhibition significantly 213 
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reduces EOC tumour burden in BRCA1/2 carriers, and Phase III trials are underway [93, 94]. Several 214 
PARP inhibitors now have FDA approval for use in EOC, for both treatment (NCT01286987)[95] and 215 
maintenance [96, 97], in platinum sensitive and platinum resistant EOC [98, 99]. 216 
Clincial Risk Predicton and Prevention of Epithelial Ovarian Cancers  217 
One of the successful advances in reducing EOC mortality over the last few years has come from 218 
identifying germline genetic variants that substantially increase a woman’s lifetime risk of disease. As 219 
discussed above, BRCA1 and BRCA2 genes are the strongest known genetic risk factors for ovarian 220 
cancer. The clinical utility of BRCA genetic testing in healthy women to inform risk reducing 221 
interventions is now well established; prophylactic bilateral salpingo-oophorectomy is commonly used 222 
to reduce EOC risks in mutation carriers, and is generally offered to BRCA1 carriers by age 40 and to 223 
BRCA2 carriers by age 45 (NCCN Guidelines 2.2017). The application of cascade testing in family 224 
members of probands has become an important intervention to prevent future cases of EOC [100]. 225 
However, the population benefits of genetic testing are limited by the low population frequency of 226 
BRCA1/BRCA2 mutations; together they have a prevalence of approximately 1 in 400 in non-227 
ashkenazi Jewish individuals in general populations of European decent and 1/40 for Ashkenazi 228 
Jewish individuals [101].  229 
Advances in next generation sequencing technologies now enable very rapid cost-effective sequence 230 
analysis of susceptibility genes for clinical use. Panel testing for known or suspected susceptibility 231 
genes is already commonly used in clinical practice, and gene panel tests for ovarian cancer have 232 
been marketed by many companies. Two different models of testing are in place; traditional gene or 233 
panel testing ordered by the patients’ physician and often billed through insurance, and a direct-to-234 
consumer model has more recently been developed where the test is ordered by the provider and the 235 
consumer meets testing costs. The development of panel testing to include BRCA1 and BRCA2 genes 236 
after the U.S. Supreme Court invalidated claims of Myriad Genetics with respect to the patenting of 237 
these genes in 2013, and the development of next generation sequencing methods has driven down 238 
sequencing costs has resulted in broader panels of genes being available for testing.  However, there 239 
are important issues in the application of panel testing [102]. For example, for many genes included in 240 
these panels the evidence that predicted pathogenic mutations are truly associated with disease is 241 
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often weak (e.g. PALB2, BARD1, NBN) [56]. For other recently identified susceptibility genes (e.g. 242 
BRIP1, RAD51C, RAD51D, MSH6) [47, 56, 57], the evidence of association with ovarian cancer risk 243 
may be strong, but the published estimates of disease penetrance associatd with mutations are 244 
imprecise, which diminishes their utlity for genetic counselling of identified carriers. Recent updates to 245 
the NCCN Guidelines recommend the consideration of risk reducing salpingo-oophorectomy in carriers 246 
of such moderate risk genes [103], although it has been suggested that this intervention be delayed 247 
until the lifetime risk of such mutation carriers exceeds 2.6%, the lifetime risk of a woman with a non-248 
BRCA family history of ovarian cancer [104].  249 
The clincial utility of genetic data is further hampered by the lack of functional ‘proof’ that germine 250 
genetic variants are disease causing, even if they are predicted to lead to protein truncation.  Large 251 
population based targeted sequencing studies performed by the research community have amplified 252 
these concerns.  A recent aggregation analysis of high-quality exome sequencing of the protein-coding 253 
genomes in 60,706 mainly disease free individuals identified more than 7 million high-quality sequence 254 
variants [105]. Of these, 179,774 different variants were predicted with high-confidence to be protein 255 
truncating variants (PTVs) through the introduction of a stop codon, frameshift, or the disruption of an 256 
essential splice site. This corresponded to an average of 85 heterozygous and 35 homozygous PTVs 257 
per individual [105]. The implication is that the human genome can tolerate a multitude of PTVs 258 
without obvious consequences on health, and so there can be no assumption of pathogencitiy when a 259 
protein coding variant is classified as a PTV.  260 
Recent genetic epidemiological studies in which thousands of ovarian cancer cases and controls have 261 
been sequenced for panels of genes, have highlighted this issue [56, 57]. Sequence analysis of 262 
several genes that function in the same DNA double strand DNA break repair pathway as BRCA1 and 263 
BRCA2 (BRIP1, NBN1, PALB2, BARD1, RAD51B, RAD51C and RAD51D), were found to have PTVs 264 
in ovarian cancer cases. In some genes (e.g. NBN1) there was no difference in the frequency of PTVs 265 
between cases and controls, suggesting that coding mutations do not confer disease susceptibility. For 266 
other genes (e.g. PALB2, BARD1 and RAD51B) there was some evidence of slightly increased 267 
ovarian cancer risks associated with PTVs, but because mutations in these genes were very rare, 268 
extremely large sample sizes will be needed to determine if mutations in these genes are truly 269 
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associated with ovarian cancer risk [56]. 270 
Another outstanding issue is the variable penetrance associated with different PTVs in the same gene 271 
and the impact this might have on clinical risk prediction. As described above, different mutations in 272 
BRCA1 and BRCA2 based on their location appear to confer different risks of breast and ovarian 273 
cancer. While most PTVs in BRCA1 and BRCA2 generally confer high penetrant disease risks, other 274 
PTVs in these genes may be associated with much lower risks. For example the average cumulative 275 
risk estimates by age 70 years for PTVs in the BRCA2 gene range from 45% for breast cancer to 11% 276 
for ovarian cancer. There are, however, examples of PTVs, particularly those towards to the 3’ end of 277 
the gene, such as K3326X, a nonsense mutation located at the 3’ end of BRCA2, being associated 278 
with much lower breast and ovarian cancer risks. A recent analysis that included more than ~76,000 279 
cancer patients and ~84,000 controls, found the K3326X variant to be a low pentrance susceptibility 280 
allele for triple-negative breast cancer (OR = 1.52) and serous invasive ovarian cancer (OR = 1.46) 281 
[106] which are considerable lower risk estimates than for other PTVs throughout this gene. It is likely 282 
that this tolerance of K3326X is reflective of the potential tolerance of proteins missing a small number 283 
of amino acids from the terminal of the BRCA2 protein, highlighting the difficulty in interpretation of 284 
PTVs, particularly those towards the 3’ end of the coding region of the gene.  285 
Polygenic and epidemiological risk prediction: Ultimately, a womans risk of ovarian cancer will be 286 
determined by a combination of genetic and epidemiological risk factors. The known susceptibility 287 
alleles identified so far account for less than half of the heritable component of ovarian cancer. It is 288 
likely that population based next generation sequencing studies will continue to identify alleles of 289 
moderate penetrance for ovarian cancer, although it is unlikely that other high penetrance genes 290 
similar to BRCA1 and BRCA2 exist. It is also anticipated that hundreds or even thousands of additional 291 
common variants conferring marginal risk associations for ovarian cancer remain to be identified [107]. 292 
Establishing a polygenic risk score (PRS) that incorporates a multitude of genetic variants could have 293 
significant clinical value in risk prediction and prevention approaches to ovarian cancer in the 294 
population.  295 
One recent study estimated the impact on the risk estimates of BRIP1 mutation carriers after 296 
incorporating additional genetic and epidemiological risk factor information [56]. Assuming the best 297 
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estimate to be the point estimate from segregation analysis performed in familes carrying BRIP1 298 
mutations, the lifetime risk of epithelial ovarian cancer in BRIP1 carriers was estimated to be 5.8%. 299 
After, incorporting information for eighteen common risk alleles for ovarian cancer, women at the 80th 300 
centile of the polygenic risk distribution based on those 18 alleles would have an expected lifetime risk 301 
of 7.2% per cent. After incorporating other risk factors for ovarian cancer into the polygenic model, 302 
specifically oral contraceptive pill use, tubal ligation, parity, a history of endometriosis and family 303 
history after removing the component due to the known genes, the lifetime risk at the 80th centile of the 304 
risk distribution increased 8.2% [56]. 305 
In summary, the clinical benefits of genetic risk prediction for carriers of high penetrance mutations in 306 
BRCA1 and BRCA2 cannot be questioned; over the last two decades, risk reducing surgery in 307 
BRCA1/BRCA2 mutation carriers has probably had a greater impact than any other clinical 308 
intervention in reducing mortality due to ovarian cancer. However, major challenges remain in 309 
translating BRCA1 and BRCA2 testing on a population scale, and in incorporating the information from 310 
for additional genetic and epidemiological risk factors for more refined risk prediction strategies. For 311 
risk alleles of more moderate pentrance, many clinical questions remain including, including: (1) Are 312 
disease risk estimates substantial and accurate enough to warrant clinical inteventions given that the 313 
only recommended clincial intervention is risk reducing surgery? (2) In the future, will functional 314 
analyses improve our understanding of the clinical significance of ovarian cancer risk variants to 315 
improve the accuracy of genetic risk prediction? (3) For individuals at more intermediate risk, what are 316 
the clinical options to reduce those risks? For example are chemopreventive strategies (e.g. oral 317 
contraceptive use) an alternative option to risk reducing surgery where the size of the elevated risks 318 
are not suffficent to warrant surgical intervention? 319 
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Table 1. Confirmed common variant susceptibility regions identified for epithelial ovarian cancer, by subtype.  
Locus Subtype# Top SNP OR (95%CI) P-value Coding Gene§ Ref. 
1p36.12 Invasive EOC-BRCA1 rs56318008 1.11 (1.07-1.16) 7.6 x10-9 CDC42 [46, 80] 
1p34.3 Invasive EOC-BRCA1 rs58722170 1.08 (1.04-1.12) 2.7 x10-12 CDCA8 [46, 80] 
2q13 BrCa-PrCa-OvCa rs17041869 0.94 (0.93–0.96) 5.1×10−9 BCL2L11 [77] 
2q13 MOC rs752590 1.34 (1.21–1.49) 3.3×10−8 PAX8 [74] 
2q13 Invasive EOC-BRCA1 rs2165109 1.09 (1.05 – 1.12) 4.2 x 10-8 ACOXL [76] 
2q31 HGSOC rs2072590 1.14  (1.10-1.19) 3.7 x10
-13 HOXD9 [67, 80] MOC rs711830 1.30 (1.20–1.40) 7.5×10−12 [74] 
3q22.3 MOC rs112071820 1.29 (1.20 – 1.37) 1.5 x 10-13 BPESC1 [76] 
3q25 HGSOC rs7651446 1.59  (1.48-1.70) 1.5 x10-38 TiPARP [69] 
3q28 LMP-SOC rs9870207 1.19 (1.12 – 1.27) 4.5 x 10-8 GMNC [76] 
4q32.3 Invasive EOC-BRCA1 rs4691139 1.20 (1.17–1.38) 3.4×10−8 TRIM61 [45] 
4q32.3 LMP-SOC rs13113999 1.23 (1.14 – 1.32) 4.7 x 10-8 TLL1 [76] 
4q26 Invasive EOC rs17329882 1.09 (1.06-1.13) 1.4 x10-8 SYNPO2 [46] 
5p15.15 HGSOC rs10069690 1.14  (1.10-1.19) 7.6 x 10
-11 TERT [70] LMP-SOC rs7705526 1.51 (1.36–1.67) 1.34 x 10-11 
5q12.3 EnOC rs555025179 1.18 (1.11 – 1.26) 4.5 x 10-8 MAST4 [76] 
6p22.1 Invasive EOC-BRCA1 rs1161331104 0.93 (0.91-0.97) 3.0 x10-8 GPX6 [46] 
8q21 HGSOC rs11782652 1.24  (1.16-1.32) 5.6 x10-11 CHMP4C [69] 
8q21.11 LMP-SOC rs150293538 2.19 (1.65 – 2.90) 2.0 x 10-9 ZFHX4 [76] 
8q24 HGSOC rs10088218 0.77 (0.73-0.82) 1.6 x10-20 MYC [67, 80] 
8q24.21 Invasive EOC-BRCA1 rs9886651 1.08 (1.05 – 1.11) 3.5 x 10-9 PVT1 [76] 
9p22 HGSOC rs3814113 0.79  (0.76-0.82) 2.7 x10-34 BNC2 [66] 
9q22.33 Invasive EOC rs1413299 1.53 (1.25–1.86) 1.88 10-8 COL15A1/ TGFBR1 [73] 
9q31 BrCa-OvCa rs200182588 0.96 (0.94–0.98) 8.9×10−9 SMC2 [75] 
9q31.1 MOC rs320203 1.29 (1.18 – 1.41) 1.7 x 10-8 GRIN3A [76] 
9q34.2 Invasive EOC-BRCA1 rs635634 1.11 (1.07-1.16) 4.4 x10-9 ABO [46] 
10p11.21 Invasive EOC rs1192691 0.89 (0.73–1.07) 2.62 10-8 NAMPTL/ ANKRD30A [73] 
10p12 HGSOC rs1243180 1.10  (1.06-1.14) 1.2 x10-9 MLLT10 [69] 
10q24.33 LMP-SOC rs7902587 1.29 (1.18 – 1.41) 4.0 x 10-8 OBFC1 [76] 
11q12 BrCa-PrCa-OvCa rs7937840 1.05 (1.03–1.06) 5.0×10−9 INCENP [75] 
12q24.31 Invasive EOC-BRCA1 rs7953249 1.08 (1.06 – 1.11) 1.1 x 10-9 HNF1A [76] 
15q26 BrCa-OvCa rs8037137 1.07 (1.05–1.10) 9.1×10−10 RCCD1 [75] 
17q11.2 Invasive EOC-BRCA1 chr17:29181220:I5 0.91 (0.88-0.94) 2.6 x10-9 ATAD5 [46] 
17q12 CCOC rs11651755 0.80 (0.72-0.88) 2.9 x10
-8 HNF1B [69, 71, 79] HGSOC rs757210 1.11  (1.07-1.15) 8.2 x10-9 
17q21.31 HGSOC rs183211 1.11  (1.07-1.16) 1.6 x10-7 PLEKHM1 [72] 
17q21.32 HGSOC rs9303542 1.14  (1.10-1.19) 4.0 x10-12 SKAP1 [69] 
18q11.2 LMP-SOC rs8098244 1.19 (1.12 – 1.27) 3.9 x 10-8 LAMA3 [76] 
19p13 Br, Pr, Ov rs1469713 0.96 (0.95–0.97) 3.4×10−10 GATAD2A [75] 
19p13 HGSOC rs4808075 1.18  (1.13-1.23) 2.9 x10-14 ABHD8 [68, 81] 
19q13.2 MOC rs688187 0.67 (0.60–0.75) 6.8×10−13 IFNL3 [74] 
22q12.1 HGSOC rs6005807 1.17 (1.11 – 1.23) 4.5 x 10-9 CHEK2 [76] 
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Figure 2. Histotype-specific associations (odds ratios) of the top SNP in six EOC susceptibility regions. The forest plots 
show the point estimates of odds ratios with the 95% confidence interval around each estimate. For each locus, the 
highlighted odds ratios and confidence intervals correspond to histotype associations at genome side significance (P< 
5x10-8). Key to ovarian cancer (OC) histotypes: M, mucinous; HGS, high grade serous; LGS, low grade serous; clear cell.
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Figure 3. Illustration of the allele frequencies and 
estimated risks for susceptibility genes and alleles 
identified from GWAS, that have been found to be 
associated with ovarian cancer predisposition  
Figure 4. Illustration of the proportional contributions of BRCA1 and BRCA2 gene mutations, 
mismatch repair (MMR) gene mutations,  BRIP1, RAD51C and RAD51 genes and common risk 
SNPs from GWAS studies to ovarian cancer risk. The know genes and risk alleles account for 
less than 50% of of the estimated heritable component of ovarian cancer
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TABLE AND FIGURE LEGENDS 620 
 621 
Table 1.  622 
#Susceptibility regions identified for different subtypes as classified by the different analyses: (1) 623 
Invasive EOC-BRCA1: Invasive epithelial ovarian cancer (EOC) cases from meta analyses that included 624 
BRCA1 carriers from the CIMBA consortium; (2) BrCa-PrCa-OvCa and BrCa-OvCa: Susceptibility loci 625 
identified from a meta-analysis of breast cancer (BrCa), prostate cancer (PrCa) and ovarian cancer 626 
(OvCa) datasets; (3) MOC: Mucinous ovarian Cancer; (4) HGSOC: High Grade Serous Ovarian Cancer; 627 
(5) LMP-SOC: Low malignant potential (borderline) and or low grade serous ovarian cancer; (6) EnOC: 628 
Endometrioid ovarian cancer; (7) CCOC: Clear Cell Ovarian Cancer. §The gene in closest proximity to 629 
the most significant ovarian cancer risk variant at each locus, or where the gene is bold and italicized, 630 
there is published functional evidence that this is the likely target gene at a locus although the gene 631 
may not be the closest in proximity to the risk associated SNP at that locus. 632 
 633 
Figure 1. Schematic representation of the Fanconi Anemia (FA)/DNA double strand break (DSB) 634 
repair pathways implicated in ovarian cancer development. Susceptibility genes where sequencing 635 
studies have identified likely pathogenic mutations in ovarian cancer populations are outlined with 636 
red dashes. 637 
 638 
Figure 2. Histotype-specific associations (odds ratios) of the top SNP in six 639 
EOC susceptibility regions. The forest plots show the point estimates of odds ratios with the 95% 640 
confidence interval around each estimate. For each locus, the highlighted odds ratios and confidence 641 
intervals correspond to histotype associations at genome side significance (P< 5x10-8). Key to ovarian 642 
cancer (OC) histotypes: M, mucinous; HGS, high grade serous; LGS, low grade serous; clear cell. 643 
 644 
Figure 3. Illustration of the allele frequencies and estimated risks for susceptibility genes and alleles 645 
identified from GWAS, that have been found to be associated with ovarian cancer predisposition. 646 
 647 
Figure 4. Illustration of the proportional contributions of BRCA1 and BRCA2 gene mutations, mismatch 648 
repair (MMR) gene mutations,  BRIP1, RAD51C and RAD51 genes and common risk SNPs from GWAS 649 
studies to ovarian cancer risk. The know genes and risk alleles account for less than 50% of of the 650 
estimated heritable component of ovarian cancer. 651 
 652 
